Zühlke – Empowering Ideas


Life Science & Pharmaceutical Industry

Patients are taking a more active and demanding role in their own healthcare, which is accelerating the transformation from disease treatment to predictive, personalised, preventive and participatory health solutions.

These, in turn, call for better understanding of patients, tailor-made support and more effective care – for dementia, diabetes and other chronic illnesses. 

Get in touch with us

For pharmaceutical companies, this requires a radical change. Big Data, the digitalisation of medicine and digital health technology are all catalysts for that change. They can get novel, more effective therapies to market faster, be patient-centred and at a lower cost. With expertise in all these fields, Zühlke creates outstanding digital patient experiences and empowers pharmaceutical companies to take a data-driven approach to diagnostics, therapy management and delivery devices.

Zuhlke pharma devices
Zuhlke pharma devices

Upgrading Tech for Personalised Medication and Diagnostics

With a direct line to our households and an unprecedented volume of our personal data, Big Tech businesses represent a big challenge to conventional healthcare companies. Changing expectations exacerbate this situation. Like society as a whole, patients and insurers now expect more individualised health advice and treatment, complementary digital care services, and value-based pricing models. It follows that the digital healthcare market will belong to those companies that successfully combine pharmaceutical know-how and patient centricity with HealthTech and trustworthy data handling.

Zühlke develops medical grade apps and devices that get medication and diagnostics fit for the future of personalised healthcare. We offer extensive experience of developing large-scale B2C platforms combined with 50 years of medical-grade expertise. With us at your side, you can gain – and maintain – leadership of your digitalised industry.

Zuhlke pharma patientenvertrauen
Zuhlke pharma patientenvertrauen

Secure Digital Solutions Build Patient Trust

Machine learning technologies analyze big healthcare data including omics and real-world patient data to help the pharmaceutical industry speed up processes and create new products and services.

Zühlke experts develop secure digital platforms that offer the industry legitimate access to the required large and meaningful volume of anonymous health data. We create positive digital experiences for patients – not least by putting them in control of their data – which helps build trust in pharmaceutical companies. Our approach combines behavioural science, user-centric healthcare apps for patients and cutting-edge technology like federated learning with superior data security.

Connecting Pharma with Ecosystem Innovation

Digital technology innovation is already having a profound impact on Pharma’s whole value chain – from AI-led clinical research and trial design, to a rapidly accelerating ecosystem of digital-first therapies, devices, platforms, and data.

Pharma Ecosystem Innovation

ePaper - 6 Principles powering Digital Health and the patient journey evolution

Pharma-tech frontrunners are using a new model for digital change. We call it Ecosystem Innovation – get started with our ePaper. 

Zuhlke pharma software 02
Zuhlke pharma software 02

Digital Therapeutics with Software as a Medical Device

Even well-established medical treatments can have serious side effects, and put a considerable burden on patients. Digital therapeutics have huge potential to meet these unmet medical needs and challenges – for example in treating mental diseases.

We can design, develop and run your digital therapeutics idea. Our software as a medical device (SaMD) solutions support – or even replace – existing diagnostics and therapies. For pharma companies, this opens up new customer segments as well as business and revenue models that are highly scalable. Compared to traditional treatments, digital therapeutics are faster and easier to distribute worldwide. We help you access this new market by developing patient-centric mobile apps that are safe and compliant with high medical standards such as IEC 62366. 

Zuhlke pharma smartsensoren 02
Zuhlke pharma smartsensoren still

Measure Patient Outcomes with Smart Connected Sensors

For pharmaceutical innovators, it is no longer enough to present study results that prove the efficacy of a new drug. You must provide irrefutable evidence that demonstrates tangible added value compared to established therapies. In line with value-based reimbursement models, this means measuring patient outcomes in real time.

Zühlke helps you do just that, for example by developing the smart connected sensors you need to collect digital biomarker data. Our solutions conform to strict procedural standards and design control. We build and run production-scale data platforms, and use machine learning to generate valuable information from the data we collect. User-friendly apps make it easy to collect the patient reported outcomes (PRO) required to complete the data sets.

Zuhlke pharma studien 02
Zuhlke pharma studien 02

Accelerate Clinical Trials with Reliable and Secure Technologies

Clinical trials account for up to 50% of R&D spending in the pharmaceutical industry. Complicated enrolment processes and high dropout rates render them inefficient and time-consuming. Digital technologies can help identify the right cohorts and make it easier for subjects to participate – minimising dropout rates and reducing cost.

Our appealing mobile applications, voice assistances and user-friendly portals improve participants’ trial experience, bringing them closer to you – and you closer to the healthcare provider. We apply our AI expertise to generate valuable insights, and the highest security standards to help establish lasting patient trust in your brand.


Jan-Philipp Koch

Business Development Manager
Contact person for Germany

Acting as innovation partner, Jan-Philipp supports companies in regulated markets such as the pharmaceutical and banking sectors in developing data-driven business models and digital solutions and processes. He brings experience as a consultant from a technology and management consulting firm and has the relevant industry insights from his previous roles at a digital health startup and a financial services company.

Albert Frömel Zühlke

Albert Frömel

Industry Lead Health & Life Sciences
Contact person for Austria

Albert Frömel is responsible for the Healthcare & Life Sciences sector in Austria He draws on years of experience with leading national and international health institutions. In doing so, he actively helped shape the solution to the most important digital challenges. His focus is on digital transformation, new intelligence systems and data-driven ecosystems. Together with his team, he empowers his clients to improve patient health outcomes, modernize work environments and ensure future-proof business models. Albert Frömel completes his technical education with a degree from the Vienna University of Economics and Business Administration and regularly gives lectures at conferences.

Nicolas Lai

Nicolas Lai

Business Development
Contact person for Singapore

Nicolas oversees the Healthcare and MedTech vertical at Zuhlke Singapore. As part of the Business Development team, he works on digital innovation initiatives together with both global and local customers. Nicolas finds joy in helping clients connect the dots, from conceptualisation to creation of exciting products.

Bardia Zanganeh

Bardia M. Zanganeh

Senior Business Development Manager
Contact person for Switzerland

Bardia M. Zanganeh is responsible for the Life Sciences and Healthcare practice in Switzerland. He serves leading healthcare institutions on all technology agenda issues. His primary areas of focus include digital innovation, business model transformation and product innovation. He also serves providers as well as medical technology and pharmaceutical companies. He has a background in engineering, consulting and entrepreneurship and is a lecturer at the University of Applied Sciences in Business Administration in Zurich.

Richard Meirion-Williams

Richard Meirion-Williams

Managing Director Business Development
Contact person for United Kingdom

Richard Meirion-Williams is the Managing Director for Business Development in the UK. Richard sits on the Executive Board in the UK.


Connie Yeung

Business Development Manager
Contact person for Hong Kong

Connie oversees the Insurance and other key business verticals in Hong Kong. She has over 10 years of experience working in both Finance and IT industry, supporting a wide range of organisations including Fortune 500 clients. With that, she has gained extensive insight into how enterprises can create better business outcomes with digital innovation. Connie is also active in foundations supporting initiatives on women leadership and women in IT.

Whitepaper: Automation of the production of bioengineered skin

The Swiss start-up company Cutiss had an ingenious idea: customised artificial skin for burns victims. In our 12-page whitepaper we describe in detail the processes that led to an effective and successful solution: An automated closed system.

whitepaper production of customized bioengineered skin

Whitepaper - How to build medical AI

Combining best practices from machine learning and medical device development: Our 17-page whitepaper explores best practices and regulatory requirements for AI in diagnostics.

whitepaper medical ai